A phase IIa trial assessed the analgesic effect and safety of ASP8477, a fatty acid amide hydrolase inhibitor, in 132 patients with painful diabetic peripheral neuropathy and postherpetic neuralgia [40]. The gene discussed is FAAH; the disease is postherpetic neuralgia.